Table 2.

Concomitait drugs that decrease occurrence of bevacizumab‐induced hypertension in FDA Adverse Event Reporting System

Drug B	Hypertension without drug B (%)	Hypertension with drug B (%)	ROR	95% CI	p‐value
EPIRUBICIN	1512/27859 (5.43)	8/429 (1.86)	0.33	0.16‐0.67	<0.001
ERLOTINIB	1486/27390 (5.43)	34/898 (3.79)	0.69	0.49‐0.97	0.035
OMEPRAZOLE	1502/27692 (5.42)	18/596 (3.02)	0.54	0.34‐0.87	0.008